Literature DB >> 10408707

Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient.

J P Elo1, P Härkönen, A P Kyllönen, O Lukkarinen, P Vihko.   

Abstract

Loss of heterozygosity at chromosome arm 16q is a frequent event in human prostate cancer. In this study, loss of heterozygosity at 16q was studied in 44 prostate cancer patients exhibiting various clinical features. Fifteen polymorphic polymerase chain reaction (PCR) markers were used to identify the separately deleted areas and the findings were compared with clinicopathological variables and 5-year survival of the patients. The results indicated that there are at least three independently deleted regions at 16q. Allelic losses at the central and distal areas were associated significantly with aggressive behaviour of the disease (16q24.1-q24.2, P < 0.01, and 16q24.3-qter, P < 0.05), and the central area of deletion was further significantly associated with poorly differentiated tumour cells (P < 0.05) and with recurrent (P < 0.01) growth of the tumour. During the follow-up period, 28% of the patients initially with M0 disease developed distant metastases. Of the patients showing allelic loss at 16q24.1-q24.2, distant metastasis were found in 45% during the 5-year follow-up period, and 31% of the patients showing loss at 16q21.1 also developed distant metastases. After the 5-year follow-up period, 14 (32%) of the patients remained alive, whereas 19 (43%) had died because of their prostate cancer. The overall survival rate of the patients showing allelic loss at 16q21.1 or 16q24.1-q24.2 was significantly lower than that of the patients with retained heterozygosity.

Entities:  

Mesh:

Year:  1999        PMID: 10408707      PMCID: PMC2362160          DOI: 10.1038/sj.bjc.6690025

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  24 in total

Review 1.  p53 function and dysfunction.

Authors:  B Vogelstein; K W Kinzler
Journal:  Cell       Date:  1992-08-21       Impact factor: 41.582

2.  Cloning and characterization of a gene that regulates cell adhesion.

Authors:  W E Pullman; W F Bodmer
Journal:  Nature       Date:  1992-04-09       Impact factor: 49.962

3.  Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma.

Authors:  U S Bergerheim; K Kunimi; V P Collins; P Ekman
Journal:  Genes Chromosomes Cancer       Date:  1991-05       Impact factor: 5.006

4.  Convenient single-step, one tube purification of PCR products for direct sequencing.

Authors:  E Werle; C Schneider; M Renner; M Völker; W Fiehn
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

5.  Cloning and characterization of a human c-myc promoter-binding protein.

Authors:  R Ray; D M Miller
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

6.  The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report.

Authors:  C B Brendler; J T Isaacs; A L Follansbee; P C Walsh
Journal:  J Urol       Date:  1984-04       Impact factor: 7.450

7.  The gene for the cell adhesion molecule M-cadherin maps to mouse chromosome 8 and human chromosome 16q24.1-qter and is near the E-cadherin (uvomorulin) locus in both species.

Authors:  K Kaupmann; J Becker-Follmann; G Scherer; H Jockusch; A Starzinski-Powitz
Journal:  Genomics       Date:  1992-10       Impact factor: 5.736

8.  Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.

Authors:  R Umbas; W B Isaacs; P P Bringuier; H E Schaafsma; H F Karthaus; G O Oosterhof; F M Debruyne; J A Schalken
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

9.  Allelic loss of chromosomes 16q and 10q in human prostate cancer.

Authors:  B S Carter; C M Ewing; W S Ward; B F Treiger; T W Aalders; J A Schalken; J I Epstein; W B Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

10.  Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization.

Authors:  T Visakorpi; A H Kallioniemi; A C Syvänen; E R Hyytinen; R Karhu; T Tammela; J J Isola; O P Kallioniemi
Journal:  Cancer Res       Date:  1995-01-15       Impact factor: 12.701

View more
  7 in total

1.  Genomewide scan for prostate cancer-aggressiveness loci.

Authors:  J S Witte; K A Goddard; D V Conti; R C Elston; J Lin; B K Suarez; K W Broman; J K Burmester; J L Weber; W J Catalona
Journal:  Am J Hum Genet       Date:  2000-05-24       Impact factor: 11.025

2.  Molecular alterations in primary prostate cancer after androgen ablation therapy.

Authors:  Carolyn J M Best; John W Gillespie; Yajun Yi; Gadisetti V R Chandramouli; Mark A Perlmutter; Yvonne Gathright; Heidi S Erickson; Lauren Georgevich; Michael A Tangrea; Paul H Duray; Sergio González; Alfredo Velasco; W Marston Linehan; Robert J Matusik; Douglas K Price; William D Figg; Michael R Emmert-Buck; Rodrigo F Chuaqui
Journal:  Clin Cancer Res       Date:  2005-10-01       Impact factor: 12.531

3.  High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays.

Authors:  Pamela L Paris; Donna G Albertson; Janneke C Alers; Armann Andaya; Peter Carroll; Jane Fridlyand; Ajay N Jain; Sherwin Kamkar; David Kowbel; Pieter-Jaap Krijtenburg; Daniel Pinkel; Fritz H Schröder; Kees J Vissers; Vivienne J E Watson; Mark F Wildhagen; Colin Collins; Herman Van Dekken
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

4.  Deletions and point mutations of LRRC50 cause primary ciliary dyskinesia due to dynein arm defects.

Authors:  Niki Tomas Loges; Heike Olbrich; Anita Becker-Heck; Karsten Häffner; Angelina Heer; Christina Reinhard; Miriam Schmidts; Andreas Kispert; Maimoona A Zariwala; Margaret W Leigh; Michael R Knowles; Hanswalter Zentgraf; Horst Seithe; Gudrun Nürnberg; Peter Nürnberg; Richard Reinhardt; Heymut Omran
Journal:  Am J Hum Genet       Date:  2009-12       Impact factor: 11.025

5.  WWOX, the common chromosomal fragile site, FRA16D, cancer gene.

Authors:  J H Ludes-Meyers; A K Bednarek; N C Popescu; M Bedford; C M Aldaz
Journal:  Cytogenet Genome Res       Date:  2003       Impact factor: 1.636

6.  Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.

Authors:  René Böttcher; Charlotte F Kweldam; Julie Livingstone; Emilie Lalonde; Takafumi N Yamaguchi; Vincent Huang; Fouad Yousif; Michael Fraser; Robert G Bristow; Theodorus van der Kwast; Paul C Boutros; Guido Jenster; Geert J L H van Leenders
Journal:  BMC Cancer       Date:  2018-01-02       Impact factor: 4.430

7.  Altered expression of 17‑β‑hydroxysteroid dehydrogenase type 2 and its prognostic significance in non‑small cell lung cancer.

Authors:  Hanna Drzewiecka; Donata Jarmołowska-Jurczyszyn; Andrzej Kluk; Bartłomiej Gałęcki; Wojciech Dyszkiewicz; Paweł P Jagodziński
Journal:  Int J Oncol       Date:  2020-03-19       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.